JP2015524474A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524474A5
JP2015524474A5 JP2015526649A JP2015526649A JP2015524474A5 JP 2015524474 A5 JP2015524474 A5 JP 2015524474A5 JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015524474 A5 JP2015524474 A5 JP 2015524474A5
Authority
JP
Japan
Prior art keywords
composition
subject
pharmaceutically acceptable
acceptable carrier
dose range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015526649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053843 external-priority patent/WO2014025814A1/en
Publication of JP2015524474A publication Critical patent/JP2015524474A/ja
Publication of JP2015524474A5 publication Critical patent/JP2015524474A5/ja
Ceased legal-status Critical Current

Links

JP2015526649A 2012-08-06 2013-08-06 治療レジメン Ceased JP2015524474A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06
US61/679,999 2012-08-06
PCT/US2013/053843 WO2014025814A1 (en) 2012-08-06 2013-08-06 Treatment regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018103554A Division JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Publications (2)

Publication Number Publication Date
JP2015524474A JP2015524474A (ja) 2015-08-24
JP2015524474A5 true JP2015524474A5 (https=) 2016-10-20

Family

ID=50068530

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015526649A Ceased JP2015524474A (ja) 2012-08-06 2013-08-06 治療レジメン
JP2018103554A Pending JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018103554A Pending JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Country Status (15)

Country Link
US (1) US9517254B2 (https=)
EP (1) EP2879680A4 (https=)
JP (2) JP2015524474A (https=)
KR (4) KR20230136142A (https=)
CN (2) CN104884060A (https=)
AU (2) AU2013299725A1 (https=)
BR (1) BR112015002687A2 (https=)
CA (1) CA2881388A1 (https=)
EA (1) EA201590349A1 (https=)
HK (2) HK1211239A1 (https=)
IL (1) IL237150B (https=)
MX (1) MX2015001695A (https=)
SG (3) SG10201709967YA (https=)
WO (1) WO2014025814A1 (https=)
ZA (1) ZA201501562B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36742A (es) * 2016-06-17 2016-12-30 S1 Biopharma Inc Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025042884A2 (en) * 2023-08-21 2025-02-27 Kuleon Llc Serotonin receptor modulators for the treatment of addictions and overdoses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2002322085A (ja) * 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
WO2004078147A2 (en) * 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
CN1946404A (zh) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
EP2389187B1 (en) * 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
EP2571360A4 (en) * 2010-05-19 2013-07-31 Univ North Carolina METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
SG10201609297VA (en) * 2011-04-04 2016-12-29 S1 Biopharma Inc Treatment regimens

Similar Documents

Publication Publication Date Title
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
JP2016535786A5 (https=)
TN2018000121A1 (en) Valbenazine salts and polymorphs thereof
JP2015501783A5 (https=)
JP2018520189A5 (https=)
JP2015523407A5 (https=)
JP2010222367A5 (https=)
MX375282B (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
CL2010000059A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer.
JP2015524474A5 (https=)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
CL2012003212A1 (es) Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson.
JP2020513032A5 (https=)
HRP20180018T1 (hr) Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
UY28218A1 (es) Compuestos arilvinilazacicloalcano y metodos de preparación y uso de ellos.
ECSP21003707A (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
JP2016515550A5 (https=)
JP2018083843A5 (https=)
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
JP2014513130A5 (https=)